Document Detail


Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.
MedLine Citation:
PMID:  23055137     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To measure interferon (IFN)-inducible chemokines in the plasma of patients with systemic sclerosis (SSc) and investigate whether the chemokine levels are correlated with disease severity.
METHODS: Plasma levels of the IFN-inducible chemokines IFNγ-inducible protein 10 (IP-10/CXCL10), IFN-inducible T cell α chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured in SSc patients and examined for correlation with the IFN gene expression signature. A composite IFN-inducible chemokine score was generated for chemokines showing a correlation with the IFN gene signature (IP-10 and I-TAC), and this score was compared between 266 patients with SSc enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort and 97 matched control subjects. Subsequently, the correlation between the IFN-inducible chemokine score at baseline and markers of disease severity was assessed. In addition, the course of the IFN-inducible chemokine score over time was examined.
RESULTS: The plasma IFN-inducible chemokine score correlated with the IFN gene expression signature, and this score was higher in SSc patients compared to controls. The IFN-inducible chemokine score was also associated with the absence of anti-RNA polymerase III antibodies and presence of anti-U1 RNP antibodies, but not with disease duration, disease type, or other autoantibodies. The chemokine score correlated with concomitantly obtained scores on the Medsger Severity Index for muscle, skin, and lung involvement in SSc, as well as the forced vital capacity, diffusing capacity for carbon monoxide, and creatine kinase levels. The association of the chemokine score with disease severity was independent of the presence of anti-U1 RNP or other potential confounders (age, sex, ethnicity, disease duration, and treatment with immunosuppressive agents). Finally, there was not a significant change in the IFN-inducible chemokine score over time.
CONCLUSION: The IFN-inducible chemokine score is a stable serologic marker of a more severe form of SSc and may be useful for risk stratification of patients, regardless of disease type (limited or diffuse) or duration of disease.
Authors:
Xiaochun Liu; Maureen D Mayes; Filemon K Tan; Minghua Wu; John D Reveille; Brock E Harper; Hilda T Draeger; Emilio B Gonzalez; Shervin Assassi
Related Documents :
18952117 - Hepatic effects of a methionine-choline-deficient diet in hepatocyte rxralpha-null mice.
25239797 - Antipruritic effect of cold stimulation at the quchi acupoint (li11) in mice.
25273567 - Genetic deletion of lxrα prevents arsenic-enhanced atherosclerosis, but not arsenic-al...
5584017 - Studies on the pathogenesis of liver necrosis by alpha-amanitin. effect of alpha-amanit...
24165567 - Glia protein aquaporin-4 regulates aversive motivation of spatial memory in morris wate...
23528627 - Cell-specific deletion of nitric oxide-sensitive guanylyl cyclase reveals a dual pathwa...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  65     ISSN:  1529-0131     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-03-17     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  226-35     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 by the American College of Rheumatology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Biological Markers
Chemokines / blood*
Child
Female
Humans
Interferons / metabolism*
Male
Middle Aged
Prognosis
Scleroderma, Systemic / immunology*,  metabolism
Severity of Illness Index
Transcriptome
Young Adult
Grant Support
ID/Acronym/Agency:
K23 AR061436/AR/NIAMS NIH HHS; K23-AR-061436/AR/NIAMS NIH HHS; KL2 RR024149/RR/NCRR NIH HHS; M01-RR-00073/RR/NCRR NIH HHS; M01-RR-01346/RR/NCRR NIH HHS; N01 AR002251/AR/NIAMS NIH HHS; N01 AR002251-013/AR/NIAMS NIH HHS; N01-AR-2251/AR/NIAMS NIH HHS; P50 AR054144/AR/NIAMS NIH HHS; P50-AR-054144/AR/NIAMS NIH HHS; R01 AR055258/AR/NIAMS NIH HHS; R01-AR-055258/AR/NIAMS NIH HHS; T32 AR052283/AR/NIAMS NIH HHS; T32-AR-052283/AR/NIAMS NIH HHS; TL1 RR024147/RR/NCRR NIH HHS; TL1-RR-024147/RR/NCRR NIH HHS; UL1 RR024148/RR/NCRR NIH HHS; UL1-RR-024148/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Chemokines; 9008-11-1/Interferons
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multifunctional nanobeacon for imaging Thomsen-Friedenreich antigen-associated colorectal cancer.
Next Document:  Oculomotor inhibition of return in normal and mindless reading.